Company intelligence / Profile preview

Avadel Pharmaceuticals

Ownership: Public · AVDL
Employees: ~194
Development stage: Commercial

Overview

Avadel’s lead product LUMRYZ™—a once-at-bedtime extended-release formulation of sodium oxybate—received FDA approval in May 2023 for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. It was granted seven years’ orphan drug exclusivity due to clinical superiority over existing twice-nightly oxybates. As of Q1 2024, >1,700 patients had initiated therapy; pediatric and idiopathic hypersomnia trials are ongoing/pending.[6][7][8]

Therapeutic areas: OtherNeurology
Modalities: Small molecules (notably sodium oxybate)[6][9]
Industry: Biotech

Drug pipeline

4 assets

LUMRYZ

Approved

3 more assets in the full pipeline.

Partnerships

RTW Investments – royalty acquisition agreement ($75M) [March 2023][7].Clinical collaborations include Stanford University on some studies/trials.[9]

Beyond the preview

Go deeper on Avadel Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avadel Pharmaceuticals.